MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Sep 18, 02:51 PM (EDT)
Price
$4.40
Change
-$0.03 (-0.68%)
Capitalization
843.47M

ABUS Arbutus Biopharma Corp Forecast, Technical & Fundamental Analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Sep 17, 2025

ABUS in +13.16% Uptrend, rising for three consecutive days on September 11, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABUS advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for ABUS moved above the 200-day moving average on September 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

The Aroon Indicator entered an Uptrend today. In of 227 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ABUS moved out of overbought territory on September 12, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where ABUS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

ABUS broke above its upper Bollinger Band on September 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.235) is normal, around the industry mean (19.637). P/E Ratio (0.000) is within average values for comparable stocks, (53.583). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.168). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (54.645) is also within normal values, averaging (331.570).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABUS is expected to report earnings to fall 425.00% to -3 cents per share on November 05

Arbutus Biopharma Corp ABUS Stock Earnings Reports
Q3'25
Est.
$-0.03
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.01
The last earnings report on August 06 showed earnings per share of 0 cents, beating the estimate of -3 cents. With 234.24K shares outstanding, the current market capitalization sits at 843.47M.
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AEYRX37.15N/A
N/A
American Century Equity Growth R
MITBX36.19N/A
N/A
MFS Massachusetts Investors Tr B
PFPPX8.04N/A
N/A
Principal MidCap Growth R3
HUDIX25.68N/A
N/A
Huber Large Cap Value Inv
JRSNX12.99N/A
N/A
JH Adaptive Risk Mgd U.S. Eq N

ABUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+0.68%
IDYA - ABUS
48%
Loosely correlated
-1.13%
ARRY - ABUS
43%
Loosely correlated
+1.16%
AXON - ABUS
42%
Loosely correlated
+0.15%
ROIV - ABUS
42%
Loosely correlated
+7.72%
BMRN - ABUS
42%
Loosely correlated
+0.83%
More